Alcon Aktie

Alcon F&U-udgifter

Forsknings- og udviklingsom­kostninger for Alcon (ALC.SW) pr. 25. aug. 2026 er 842,85 Mio. USD. I foregående år var Forsknings- og udviklingsom­kostninger 711,93 Mio. USD — en ændring på 18,39 % (højere).

F&U-udgifter

842,85 Mio.USD

YoY

18,39%

Senest opdateret:

Forsknings- og udviklingsom­kostninger for Alcon er 2026 842,85 Mio. USD. Forsknings- og udviklingsom­kostninger for Alcon var 2025 711,93 Mio. USD. Det falder dermed med 18,39% højere sammenlignet med året før.

Alcon F&U-udgifter historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

F&U-udgifter
Date
F&U-udgifter
1. jan. 2018
477,06 Mio. USD
1. jan. 2019
533,13 Mio. USD
1. jan. 2020
546,95 Mio. USD
1. jan. 2021
684,30 Mio. USD
1. jan. 2022
570,52 Mio. USD
1. jan. 2023
698,11 Mio. USD
1. jan. 2024
711,93 Mio. USD
1. jan. 2025
842,85 Mio. USD
Alcon F&U-udgifter historik
ÅRF&U-udgifterYoY
842,85 Mio.USD+18,39%
711,93 Mio.USD+1,98%
698,11 Mio.USD+22,36%
570,52 Mio.USD-16,63%
684,30 Mio.USD+25,11%
546,95 Mio.USD+2,59%
533,13 Mio.USD+11,75%
477,06 Mio.USD+0,51%
474,62 Mio.USD+17,03%
405,54 Mio.USD-48,29%
784,26 Mio.USD
Access this data via the Eulerpool API

Alcon Aktieanalyse

Hvad laver Alcon? Alcon AG is a leading company in ophthalmology with more than 70 years of experience in this industry. The company was founded in 1945 by Robert Alexander and William Conner and has its headquarters in Geneva, Switzerland. Alcon AG has been part of the Novartis Group since 2019 and is a leader in the production of ophthalmic products. The business model of Alcon AG is based on the manufacturing and sale of ophthalmic products. The company offers medical products such as contact lenses, surgical instruments, eye drops, and intraocular lenses. Alcon AG specializes in the development of products that can be used for various eye diseases. The company provides a wide range of products that can be used by ophthalmologists and opticians. The various divisions of Alcon AG include eye care products, surgical products, and diagnostic products. Eye care products, such as contact lenses, offer consumers a safe and easy way to correct their vision. Surgical products include a wide range of instruments used in eye surgeries. Diagnostic products help identify eye diseases and support treatment. Alcon AG specializes in the development of products for the treatment of eye diseases. These include conditions such as cataracts, glaucoma, and age-related macular degeneration. The company offers various products that can be used for these conditions, such as eye drops to reduce elevated eye pressure in glaucoma. It has also developed a wide range of products for refractive correction, allowing people to improve their vision. Alcon AG works closely with leading ophthalmologists and opticians to optimize its product development. This close collaboration ensures that Alcon AG's products meet the needs of patients and provide them with high safety and effectiveness. With its innovative products and technologies, Alcon AG aims to improve the quality of life for patients and provide them with optimal care and treatment. Overall, Alcon AG is a leading company in ophthalmology, offering its customers a wide range of innovative and high-quality products. From diagnosis to care to surgical interventions, Alcon AG's product range covers all areas of ophthalmology. The company is known for its research and development and is constantly working towards advancing ophthalmology. Through its continuous innovation and customer orientation, Alcon AG has established a strong position in the healthcare industry and will continue to introduce new products and technologies in the future. Alcon er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Alcon aktie

Forsknings- og udviklingsom­kostninger for Alcon er 842,85 Mio. USD i 2026.

Forsknings- og udviklingsom­kostninger for Alcon ændrede sig fra 711,93 Mio. USD til 842,85 Mio. USD, hvilket repræsenterer en ændring på 18,39 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Forsknings- og udviklingsom­kostninger Alcon siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

F&U-omkostninger repræsenterer de omkostninger, der opstår ved forskning og udvikling af nye produkter, tjenester eller processer. Høje F&U-udgifter kan signalere innovation og fremtidigt vækstpotentiale.

Forsknings- og udviklingsom­kostningers USD er en vigtig faktor for investorer. Ændringer i denne nøgletal kan signalere forbedrede eller forværrede fundamentale forhold, hvilket kan påvirke aktiekursen. På Eulerpool kan du følge Forsknings- og udviklingsom­kostningers Alcon historisk.

Access this data via the Eulerpool API

Resultatopgørelse — Alcon

Alle nøgletal — Alcon